Neil R. Hartman - Concepedia

Author

Neil R. Hartman

Also Known As

N R Hartman, N. R. Hartman, N.R. Hartman, NEIL R. HARTMAN, Neil G. Hartman, Neil Hartman, Neil R Hartman, Neil R. Hartman

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

National Institutes of Health National Cancer Institute Center for Drug Evaluation and Research United States Food and Drug Administration Mayo Clinic

About

Neil R. Hartman is an author at National Institutes of Health specializing in medicine, pharmacology, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	15	1K
2	Biochemistry	7	7	164
3	Natural Sciences	4	4	88
4	Cell Biology	2	2	308
5	Health Sciences	1	1	16

Neil R. Hartman

Publications

2.1K

Citations

H-Index

Page 1

	Year	Citations
In Vivo Activity Against HIV and Favorable Toxicity Profile of 2′,3′-Dideoxyinosine Robert Yarchoan, Hiroaki Mitsuya, Rose V. Thomas, Science	1989	425
Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3'-azido-2'3'-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine. Carlo Federico Perno, Robert Yarchoan, David A. Cooney, The Journal of Experimental Medicine Human Immunodeficiency VirusViral ProductionRelated CongenersHuman RetrovirusImmunology	1989	290
Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides. Carlo Federico Perno, Robert Yarchoan, David A. Cooney, The Journal of Experimental Medicine Several DideoxynucleosidesHuman Immunodeficiency VirusMedicineHuman RetrovirusRelated 2',3'-Dideoxynucleosides	1988	232
Factors determining the activity of 2',3'-dideoxynucleosides in suppressing human immunodeficiency virus in vitro. David A. Cooney, Neil R. Hartman, Carlo Federico Perno, Molecular Pharmacology	1988	160
Pharmacokinetics of 2′, 3′-dideoxyadenosine and 2′, 3′-dideoxyinosine in patients with severe human immunodeficiency virus infection Neil R. Hartman, Robert Yarchoan, James M. Pluda, Clinical Pharmacology & Therapeutics Therapeutic Drug MonitoringPlasma KineticsDrug InfusionAcquired Immunodeficiency SyndromeBioanalysis	1990	133
Characterizing the reproducibility in using a liver microphysiological system for assaying drug toxicity, metabolism, and accumulation Andrés M. Rubiano, Amruta Indapurkar, Ryosuke Yokosawa, Clinical and Translational Science	2020	89
Reaction of Geldanamycin and C17-Substituted Analogues with Glutathione: Product Identifications and Pharmacological Implications Richard L. Cysyk, Robert Parker, Joseph J. Barchi, Chemical Research in Toxicology	2006	84
Potent DNA chain termination activity and selective inhibition of human immunodeficiency virus reverse transcriptase by 2',3'-dideoxyuridine-5'-triphosphate. David A. Cooney, David Farquhar, Carlo Federico Perno, Molecular Pharmacology	1990	78
Pharmacokinetic Analysis of Dextran Sulfate in Rats as Pertains to Its Clinical Usefulness for Therapy of HIV Infection Neil R. Hartman, David G. Johns, Hiroaki Mitsuya AIDS Research and Human Retroviruses Pharmacological StudyMedicineImmunologyHiv InfectionRadiopharmaceutical Therapy	1990	75
The National Cancer Institute Phase I Study of 2′,3′-Dideoxyinosine Administration in Adults with AIDS or AIDS-Related Complex: Analysis of Activity and Toxicity Profiles Robert Yarchoan, Hiroaki Mitsuya, James M. Pluda, Clinical Infectious Diseases Primary ImmunodeficiencyHuman Immunodeficiency VirusCd4+ CellsMedicineHuman Retrovirus	1990	68

Page 1